Please login to the form below

Not currently logged in


This page shows the latest GVHD news and features for those working in and with pharma, biotech and healthcare.

FDA approves first drug to prevent graft-versus-host disease

FDA approves first drug to prevent graft-versus-host disease

The approval is based on data from two trials. In the phase 2 GVHD-1 study, while patients who received Orencia saw a 97% overall survival rate compared to 84% for ... The second trial, a clinical study known as GVHD-2, used real-world data collected by

Latest news

More from news
Approximately 2 fully matching, plus 24 partially matching documents found.

Latest Intelligence

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Subscribe to our email news alerts


Add my company

Accession was a born from a passion and a vision. A passion to harness the power of market access to...

Latest intelligence

New Playbook Alert: Virtual Patient Engagement
Millennials: the wellness generation
Looking at the results from a global healthcare research study focusing on the patients of the future...
The problem with clinical trials (and how virtual insight-gathering can help)
While still the gold standard of research, clinical trials are often riddled with issues that limit their applicability to broader populations or delay market access....